Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Net Income (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Net Income for 6 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 316.72% year-over-year to $11.1 million, compared with a TTM value of $554000.0 through Dec 2025, up 101.01%, and an annual FY2025 reading of $554000.0, up 101.01% over the prior year.
  • Net Income was $11.1 million for Q4 2025 at Xeris Biopharma Holdings, up from $621000.0 in the prior quarter.
  • Across five years, Net Income topped out at $11.1 million in Q4 2025 and bottomed at -$50.8 million in Q4 2021.
  • Average Net Income over 5 years is -$16.7 million, with a median of -$16.3 million recorded in 2023.
  • The sharpest move saw Net Income tumbled 132.37% in 2021, then soared 316.72% in 2025.
  • Year by year, Net Income stood at -$50.8 million in 2021, then soared by 74.54% to -$12.9 million in 2022, then dropped by 3.56% to -$13.4 million in 2023, then surged by 61.81% to -$5.1 million in 2024, then skyrocketed by 316.72% to $11.1 million in 2025.
  • Business Quant data shows Net Income for XERS at $11.1 million in Q4 2025, $621000.0 in Q3 2025, and -$1.9 million in Q2 2025.